Abstract:To achieve targeted, truly systemic therapeutic gene delivery to tumors, we exploited the observation that infection by a retrovirus proceeds initially through a non-specific adsorption stage prior to envelope-receptor recognition/internalization. Antigen specific, primary murine OT-1 T cells can be incubated in vitro with retroviral stocks which adhere to the cell surface. In vitro, virus can be handed off to target cells upon co-culture with the T cells, dependent upon cell contact, envelope/receptor interactions and local heparanase expression as provided by T cell activation upon encounter of antigen (ovalbumin) by the OT-1 T cells. Retroviral particles, pre-adsorbed to the surface of OT-1 T cells in vitro, were available for hand off in vivo to B16ova tumors distant from the site of T cell injection at high enough concentrations for therapeutic levels of gene transfer to occur. We have now delivered a variety of therapeutic genes to tumors, including HSVtk, IL-12 and the chemokine CCL-21. Pre- adsorption of vectors encoding each of these genes has led to therapeutic benefits in terms of direct local cell killing (HSVtk in combination with lymphodepletion), generation of potent immunizing activity (IL-12) and significant enhancement of the efficacy of subsequent doses of adoptively transferred, unmodified T cells (CCL-21). We have also characterized a second pathway by which viral particles expressing no envelope (BALD particles) can be handed off from T cells dependent upon T cell activation. Release of viral particles from the T cell surface coincides with the penetration of perforin-containing cytotoxic vesicles from the antigen activated T cells. The endosomolytic properties of perforin promote release of these viral particles from the endosome and, in situations where direct T cell killing does not occur, the virus goes onto to generate a productive infection. Thus, T cell mediated delivery of MLV core particles can be used to deliver therapeutic retroviral vectors in vivo using targeting at the level of T cell activation, thereby dispensing with the need to target viral envelopes. We have also investigated the possibilities of using antigen specific T cells to deliver replication competent viruses to tumors both in vitro and in vivo. In particular, we have demonstrated that replication competent Vesicular Stomatitis virus expressing GFP can be used to load OT-1 T cells. The virus infects these T cells only at very low levels and does not kill them. However, the T cells produce VSV particles at appreciable levels 48-72 hours post loading suggesting that they may be able to carry the viruses to tumors in vivo and lead to productive infection following intratumoral T cell accumulation. Therefore, the protection, concentration, and targeted delivery of viruses by T cell carriers offers great potential for the delivery of vector stocks into the circulation of patients. By careful selection of the virus, and therapeutic gene that is used, significant synergy can be achieved over the use of virotherapy, or adoptive T cell therapy, alone.

An Optimized Gene Transfection System in WERI-Rb1 Cells.

The Use of rAAV2-<i>RB1</i>-Mediated Gene Therapy in Retinoblastoma

Construction of recombinant lentivirus vector containing retinoic acid-induced gene G and its effect on human lung cancer A549 cell line

The Role of Recombinant Rb Gene Adenovirus Vector in the Growth of Lung Adenocarcinoma Cells

Intraocular Sirna Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Gene

222 Formulation of a Novel High Performance Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

A Novel Treatment Approach for Retinoblastoma by Targeting Epithelial Growth Factor Receptor Expression with a Shrna Lentiviral System

Regulated Differentiation of WERI-Rb-1 Cells into Retinal Neuron-Like Cells

Expression of the Human Retinoblastoma Gene Product pp1 10RB in Insect Cells Using the Baculovirus System

Transfection and expression of retrovirus-mediated reporter genes in retinal pigment epithelial cells in vitro

Homologous Recombination-Based Adenovirus Vector System for Tumor Cell-Specific Gene Delivery

VEGF-Targeted RNA Interference Suppresses Angiogenesis and Tumor Growth of Retinoblastoma

812. Cellular Delivery of Gene Therapy Vectors

Enhanced Transduction and Improved Photoreceptor Survival of Retinal Degeneration by the Combinatorial Use of Raav2 with a Lower Dose of Adenovirus

Efficient Transduction of Corneal Stroma by Adeno-Associated Viral Serotype Vectors for Implications in Gene Therapy of Corneal Diseases

Efficient retinal ganglion cells transduction by retro-orbital venous sinus injection of AAV-PHP.eB in mature mice

Combination of Oncolytic Adenovirus and Endostatin Inhibits Human Retinoblastoma in an in Vivo Mouse Model

High--efficient Genetic Transfection of CD41~(+), UT7, U937 and MDA--MB--435 Cells with a Recombined Murine Stem Cell Retroviral Vector

Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine Against Retinoblastoma Cells

AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes

Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters